|
02 Mar 2019 |
Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
|
|
02 Mar 2019 |
Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
|
|
28 Feb 2019 |
Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization
|
|
15 Feb 2019 |
New Clinical Data Analysis Shows Survival Benefit Three Years after Treatment with Sipuleucel-T
|
|
14 Feb 2019 |
Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer
|
|
13 Feb 2019 |
Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
|
|
13 Feb 2019 |
Affinivax, Inc. Announces Initiation of Phase 1/2 Clinical Study of ASP3772, Its Novel Pneumococcal MAPS Vaccine, in Collaboration with Astellas
|
|
12 Feb 2019 |
FluGen’s M2SR Influenza Vaccine Succeeds in Phase 2 Human Challenge Trial Against a Highly Mismatched Virus
|
|
04 Feb 2019 |
VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine
|
|
31 Jan 2019 |
Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate
|
|
30 Jan 2019 |
Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents
|
|
29 Jan 2019 |
Takeda’s Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial
|
|
24 Jan 2019 |
Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests
|
|
24 Jan 2019 |
Bavarian Nordic Advances Development of Equine Encephalitis Virus Vaccine
|
|
21 Jan 2019 |
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and Regeneron’s Cemiplimab in Oropharyngeal Cancer
|
|
17 Jan 2019 |
United Neuroscience Announces Positive Top-Line Results from Phase 2a Clinical Study of UB-311 Vaccine in Patients with Alzheimer's Disease
|
|
17 Jan 2019 |
AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial
|
|
17 Jan 2019 |
First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
|
|
15 Jan 2019 |
FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination
|
|
08 Jan 2019 |
PrimeVax Immuno-Oncology Receives IND Permission From FDA
|
|
07 Jan 2019 |
Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate
|
|
03 Jan 2019 |
Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009
|
|
30 Dec 2018 |
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax
|
|
27 Dec 2018 |
FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
|
|
22 Dec 2018 |
Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17
|
